SARC024: A Blanket Protocol to Study Oral Regorafenib in Patients With Selected Sarcoma Subtypes

NCT02048371 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

131

Enrollment

OTHER

Sponsor class

Conditions

Liposarcoma
Osteogenic Sarcoma
Ewing/Ewing-like Sarcoma
Rhabdomyosarcoma
Mesenchymal Chondrosarcoma

Interventions

DRUG: Regorafenib
DRUG: Placebo

Sponsor

Sarcoma Alliance for Research through Collaboration